• Zum Hauptinhalt springen
  • Zum Footer springen
  • Deutsch - de
  • English - en

    SyNergy - Mu...

    • About
      • About us
      • Our Measures
      • Members
      • Cluster Management
      •  PhD & Postdoc representatives
      • Scientific Advisory Board
      •  International cooperation partners
      • Timeline
      •  Media Kit
      • Contact
    • News & Events
      • News
      • Events
      • In the News
      • Open Positions
    • Research
      • Publications
      • Our Research Focus
      • Technology Hubs
      • Research Spotlight
      • Research Data Management
      • Sustainability Initiative
      •  Code of Conduct
    • Science & Society
      • For Schools & Students
      • Public Events
      • Podcasts
      • Videos
    • Support for Diversity & Equity
      • Newcomer Center
      • Gender Equality Program
      • Early Career Investigator Program
    1. Home
    2. News & Events
    3. News
    4. Ion channel as possible target structure for therapies
    News | 11/08/2022 | Press Release

    Ion channel as possible target structure for therapies

    In certain neurodegenerative diseases, metabolic by-products build up in cells. The modulation of an ion channel could offer a new therapeutic approach.

    Lysosomal storage diseases are inherited disorders of the metabolism. They originate in various dysfunctions of lysosomes. With the aid of enzymes, these organelles break down components from their own cell as well as from other cells. Disease-causing genetic mutations lead to defects in enzymes or to membrane structures of the lysosomes. As a consequence, there is a build-up of biological macromolecules – initially in cells but spreading later throughout the organism. This results in lysosomal storage diseases with neurodegenerative symptoms, which typically begin in early childhood and go along with greatly reduced life expectancy and quality of life. LMU pharmacologist Prof. Christian Grimm from the Walther Straub Institute of Pharmacology and Toxicology, working in cooperation with SyNergy member Prof. Dominik Paquet (Institute for Stroke and Dementia Research, University Hospital, LMU Munich) and other researchers, has now managed to modulate a specific cation channel in lysosomes.

    • Press release LMU

    Participating Universities
     LMU logo in white
     TUM logo in white
    Partner Institutions
     Logo DZNE in white
    Helmholtz Munich logo in white 
     Logo Max Planck Gesellschaft 

    SyNergy is funded by the Deutsche Forschungsgemeinschaft (German Research Foundation) within the framework of the German Excellence Strategy (EXC 2145 SyNergy – ID 390857198). The Excellence Strategy promotes outstanding research at German universities. 

    Contact

    Munich Cluster for Systems Neurology (SyNergy)

    Feodor-Lynen-Str. 17
    81377 Munich
    +49 (0)89 4400-46497
    yüubg,ybc;јuidpxј_vfulJyz mi
    Editor login
    Imprint | Data-Safety